panCELLa was co-founded in 2015 by Drs Andras Nagy, PhD, stem cell biologist and Armand Keating, MD, PhD, clinical scientist and haematologist. The two expertise represented by the co-founders were a perfect combination to create a unique conceptual framework of a company aiming to move cell therapy to broad clinical applications.

panCELLa is a privately-held early-stage biotechnology firm based on the innovative technology developed in Dr Andras Nagy’s lab at the Sinai Health System (SHS). panCELLa has built on two exclusive platforms; FailSafe™ and induced Allogeneic Cell Tolerance (iACT or Stealth Cells™) that allow for the development of safe, universal, cost-effective, “off-the-shelf” therapeutic cell products for medicine through genome editing services and licensing their technologies.

panCELLa continues its internal R&D efforts to develop additional novel uses of its platforms in areas such as bio-production, cancer vaccination and tolerization.